The Association for Accessible Medicines, a trade organization for drugmakers producing generics, is undergoing an internal riff that may jeopardize its lobbying power. This follows substantial financial losses and a series of high-profile layoffs. Group insiders lay part of the blame on the board of directors who they argue repeatedly fumbled key organizational decisions.
According to Megan R. Wilson and Alice Miranda Ollstein, “While the people said AAM has a promising vision for elevating the generic and biosimilar industries, they worry the group may be too under-resourced to execute it. And a diminished trade group for the industry could have negative consequences for its members.”
To read more, click here.
(Source: Politico, April 13th, 2023)